| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Associate Editors
|
|
|
2014
|
24 |
S1 |
p. i-
1 p.
|
artikel
|
| 2 |
Author index
|
|
|
2014
|
24 |
S1 |
p. S53-S56
4 p.
|
artikel
|
| 3 |
Copyright
|
|
|
2014
|
24 |
S1 |
p. vi-
1 p.
|
artikel
|
| 4 |
Editor Emeritus
|
|
|
2014
|
24 |
S1 |
p. i-
1 p.
|
artikel
|
| 5 |
Editorial Board
|
|
|
2014
|
24 |
S1 |
p. i-
1 p.
|
artikel
|
| 6 |
Editor-in-Chief (Europe & RoW)
|
|
|
2014
|
24 |
S1 |
p. i-
1 p.
|
artikel
|
| 7 |
Editor-in-Chief (The Americas)
|
|
|
2014
|
24 |
S1 |
p. i-
1 p.
|
artikel
|
| 8 |
GP1-2: Autocrine human growth hormone suppression of E-CADHERIN via p44/42 MAPK promotes epithelial-tomesenchymal transition (EMT) of colorectal carcinoma cells
|
Wang, J.
|
|
2014
|
24 |
S1 |
p. S25-
1 p.
|
artikel
|
| 9 |
GP4-5: Circulating levels of insulin-like growth factor-1(IGF-I)/insulin-like growth factor binding protein-3 (IGFBP-3) in obese patients: the state of type 2 diabetes
|
Kim, M.S.
|
|
2014
|
24 |
S1 |
p. S48-S49
2 p.
|
artikel
|
| 10 |
GP2-6: Differential effects of IGFBP-6 on migration of two ovarian cancer cell lines
|
Bach, L.
|
|
2014
|
24 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 11 |
GP3-4: Discordance of post-surgical nadir GH during OGTT and serum IGF-I levels in patients with acromegaly
|
Fukuda, I.
|
|
2014
|
24 |
S1 |
p. S38-
1 p.
|
artikel
|
| 12 |
GP4-6: Effects of GH/IGF-I axis on retinal vascular morphology: retinal vascular morphology in Laron syndrome
|
Sekeroglu, H.T.
|
|
2014
|
24 |
S1 |
p. S49-
1 p.
|
artikel
|
| 13 |
GP4-2: Effects of heparin administration on the generation of IGFBP-4 fragments during PCI treatment of ST-elevation myocardial infarction patients
|
Hjortebjerg, R.
|
|
2014
|
24 |
S1 |
p. S47-S48
2 p.
|
artikel
|
| 14 |
GP4-3: Epigenetic analyses of the insulin-like growth factor binding protein 1 gene in diabetes and diabetic nephropathy
|
Gu, T.
|
|
2014
|
24 |
S1 |
p. S48-
1 p.
|
artikel
|
| 15 |
GP3-1: Growth hormone (GH) replacement has a beneficial effect on glycosylated haemoglobin (HbA1c) levels in adult patients with GH deficiency (GHD) enrolled in the NordiNet® International Outcome Study (IOS)
|
Weber, M.M.
|
|
2014
|
24 |
S1 |
p. S37-
1 p.
|
artikel
|
| 16 |
GP1-1: Growth hormone targets expression of specific lipolytic genes to promote lipolysis of white adipose tissue
|
Law, Y.Y.
|
|
2014
|
24 |
S1 |
p. S25-
1 p.
|
artikel
|
| 17 |
GP2-5: Hyperglycaemia induces chemo-resistance of breast cancer cells via regulating IGFBP-2/oestrogen receptor (ERa) interactions: role of ERa phosphorylation
|
Zeng, L.
|
|
2014
|
24 |
S1 |
p. S28-
1 p.
|
artikel
|
| 18 |
GP2-1: IGF-I ameliorates hepatic fibrosis in mouse models of nonalcoholic steatohepatitis and cirrhosis via inhibiting the activity or hepatic stellate cells
|
Nishizawa, H.
|
|
2014
|
24 |
S1 |
p. S27-
1 p.
|
artikel
|
| 19 |
GP2-4: Insulin-like growth factor binding protein (IGFBP)-1 and its RGD domain: favorable in vivo actions in glucose regulation
|
Haywood, N.
|
|
2014
|
24 |
S1 |
p. S28-
1 p.
|
artikel
|
| 20 |
GP4-1: Loss of PI 3-kinase-binding protein PI3KAP/XB130 suppresses thyroid function and induces enlargement of thyroid glands in mice
|
Yamanaka, D.
|
|
2014
|
24 |
S1 |
p. S29-
1 p.
|
artikel
|
| 21 |
GP1-6: Metabolic requirements to sustain NEFA and glucose homeostasis overrides the role of growth hormone in promoting rapid linear growth in hyperphagic MC4RKO mice
|
Tan, H.Y.
|
|
2014
|
24 |
S1 |
p. S37-
1 p.
|
artikel
|
| 22 |
GP3-6: Mixed effects PK/PD modelling of NNC0195-0092 - a noncovalent albumin binding growth hormone derivative in the hypophysectomised rat
|
Thygesen, P.
|
|
2014
|
24 |
S1 |
p. S39-
1 p.
|
artikel
|
| 23 |
GP1-4: Mortality in patients with non-functioning pituitary adenoma with and without growth hormone replacement therapy. A case-controlled study in more than 400 patients
|
Trimpou, P.
|
|
2014
|
24 |
S1 |
p. S36-
1 p.
|
artikel
|
| 24 |
GP1-5: Presurgical somatostatin analogue versus direct surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis, assessing clinical evidence using the GRADE system
|
Nunes, V.S.
|
|
2014
|
24 |
S1 |
p. S36-
1 p.
|
artikel
|
| 25 |
GP4-7: ProIGF-II not matureIGF-II promotes estrogen independent breast cancer growth and metastasis in a SCID and Nude mouse model: differential signallng mechanisms thru IGF and Insulin receptors and phosphorylation/activation of estrogen and progesterone receptors
|
Jian, T.
|
|
2014
|
24 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 26 |
GP1-3: Role of growth hormone (GH) signaling pathways in the development of atherosclerosis
|
Ishikawa, M.
|
|
2014
|
24 |
S1 |
p. S26-
1 p.
|
artikel
|
| 27 |
GP3-2: Rosiglitazone treatment: acromegaly patients do not differ from normal type 2 diabetics in their IGFBP-1 and Insulin dynamics with euglycemic glucose clamp
|
Tint, M.T.
|
|
2014
|
24 |
S1 |
p. S37-S38
2 p.
|
artikel
|
| 28 |
GP4-4: SGA short stature bearing with a novel nonsense mutation (p.W1219X) in the IGF1R gene
|
Fujimoto, M.
|
|
2014
|
24 |
S1 |
p. S48-
1 p.
|
artikel
|
| 29 |
GP2-2: The deubiquitinating enzyme, USP9X positively regulates insulin-like growth factor (IGF)-dependent cell growth by inhibition of degradation of IGF-I receptor (IGF-IR) and insulin receptor substrate (IRS)-2 in prostate cancer cells
|
Furuta, H.
|
|
2014
|
24 |
S1 |
p. S27-
1 p.
|
artikel
|
| 30 |
GP3-3: The diagnostic accuracy of pegvisomant-primed glucagon stimulation test (PV-GST) compared to insulin tolerance (ITT) and glucagon stimulation (GST) tests in evaluating adult growth hormone (GH) reserve
|
Yuen, K.C.J.
|
|
2014
|
24 |
S1 |
p. S38-
1 p.
|
artikel
|
| 31 |
GP2-7: The IGF/IGFR pathway regulates axial patterning during early neural development in mammal
|
Takata, N.
|
|
2014
|
24 |
S1 |
p. S29-
1 p.
|
artikel
|
| 32 |
GP2-3: The role of the insulin receptor in breast cancer progression
|
Rostoker, R.
|
|
2014
|
24 |
S1 |
p. S27-S28
2 p.
|
artikel
|
| 33 |
GP3-5: Thyroid hormone activation regulates exercise induced growth hormone release
|
Ignacio, D.L.
|
|
2014
|
24 |
S1 |
p. S38-
1 p.
|
artikel
|
| 34 |
OR5-3: A GH antagonist fusion with GH binding protein is biologically active, shows delayed clearance and inhibits growth in a rabbit model
|
Wilkinson, I.
|
|
2014
|
24 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 35 |
OR5-6: Amplified stem/progenitor cells in a mouse model of prostate tumorigenesis induced by autocrine prolactin
|
Sackmann Sala, L.
|
|
2014
|
24 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 36 |
OR8-4: A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies
|
Sun, J.
|
|
2014
|
24 |
S1 |
p. S22-
1 p.
|
artikel
|
| 37 |
OR7-8: A phase II randomised, open-label, parallelgroup study of the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in adult patients with acromegaly
|
Trainer, P.J.
|
|
2014
|
24 |
S1 |
p. S21-
1 p.
|
artikel
|
| 38 |
OR7-4: A phase 2, six-month dose-response study to investigate TransCon hGH, a long-acting hGH, in treatment naïve children with idiopathic growth hormone deficiency (IGHD)
|
Chatelain, P.
|
|
2014
|
24 |
S1 |
p. S19-
1 p.
|
artikel
|
| 39 |
OR7-1: A reversible albumin-binding GH derivative possesses a promising once-weekly treatment profile and is well tolerated in adult subjects with growth hormone deficiency
|
Højby Rasmussen, M.
|
|
2014
|
24 |
S1 |
p. S18-
1 p.
|
artikel
|
| 40 |
OR5-5: Autocrine hGH stimulated miRNA 96-182-183 cluster promotes epithelial-mesenchymal transition and invasion in breast cancer
|
Zhang, W.
|
|
2014
|
24 |
S1 |
p. S15-
1 p.
|
artikel
|
| 41 |
OR1-6: Combination medical therapy for acromegaly: the ACROSTUDY experience
|
Strasburger, C.
|
|
2014
|
24 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 42 |
OR2-6: Cyclic glycine-proline is a regulator that dynamically controls IGF-1 homeostasis through altering IGF-1 binding to IGFBP3
|
Guan, J.
|
|
2014
|
24 |
S1 |
p. S9-
1 p.
|
artikel
|
| 43 |
OR6-6: Dermal fibroblast secreted IGF-I protects skin keratinocytes against ultraviolet B radiation induced damage
|
Fernandez, T.L.
|
|
2014
|
24 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 44 |
OR6-1: Dicarba modification of insulin peptides results in lower mitogenic activity signaled via IGF-1R and IR than insulin
|
Ong, S.C.
|
|
2014
|
24 |
S1 |
p. S16-
1 p.
|
artikel
|
| 45 |
OR6-3: Early postnatal nutritional programming of growth involves GHRH neurons axon growth stimulation by leptin & IGF-I
|
Decourtye, L.
|
|
2014
|
24 |
S1 |
p. S17-
1 p.
|
artikel
|
| 46 |
OR2-4: Exogenous administration of protease-resistant, non matrixbinding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
|
Soh, C.-L.
|
|
2014
|
24 |
S1 |
p. S8-
1 p.
|
artikel
|
| 47 |
OR3-4: GH activated signal transducer and activator of transcription 5 is required for induction of beige fat in inguinal white adipose tissue
|
Nelson, C.N.
|
|
2014
|
24 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 48 |
OR3-2: GH enhances spine density in amygdalar neurons
|
Gisabella, B.
|
|
2014
|
24 |
S1 |
p. S10-
1 p.
|
artikel
|
| 49 |
OR1-1: GH treatment modulates mortality in adult onset GH deficiency and a discordant socio-economic status is apparent
|
Stochholm, K.
|
|
2014
|
24 |
S1 |
p. S5-
1 p.
|
artikel
|
| 50 |
OR4-2: Growth hormone is a more potent growth stimulating hormone than IGF-I: clinical perspective
|
Laron, Z.
|
|
2014
|
24 |
S1 |
p. S12-
1 p.
|
artikel
|
| 51 |
OR4-5: IGF bioactivity in sera and pleural effusions from patients suspected of lung cancer
|
Espelund, U.
|
|
2014
|
24 |
S1 |
p. S13-
1 p.
|
artikel
|
| 52 |
OR2-1: Impaired mTORC1 activity up-regulates IGFBP-1 synthesis during dietary protein restriction
|
Takenaka, A.
|
|
2014
|
24 |
S1 |
p. S7-
1 p.
|
artikel
|
| 53 |
OR1-2: Impairment of anaerobic capacity in adults with growth hormone deficiency
|
Chikani, V.
|
|
2014
|
24 |
S1 |
p. S5-
1 p.
|
artikel
|
| 54 |
OR8-7: Insulin like growth factor-II (IGF-II) regulates mitochondrial phenotype, metabolism and DNA content to prevent apoptosis and to increase energy production efficiency promoting a more aggressive and chemoresistant breast cancer disease
|
Radhakrishnan, V.K.
|
|
2014
|
24 |
S1 |
p. S23-
1 p.
|
artikel
|
| 55 |
OR8-2: Insulin-like growth factor receptor inhibition in mammary epithelium enhances Wnt1- mediated tumors, canonical Wnt signaling and IGF-II/insulin-receptor A expression
|
Wood, T.L.
|
|
2014
|
24 |
S1 |
p. S21-S22
2 p.
|
artikel
|
| 56 |
OR8-1: Insulin receptor substrate (IRS)-1 interacts with protein arginine methyltransferase 5 (PRMT5), emerging as a novel regulator of alternative pre-mRNA splicing
|
Ozoe, A.
|
|
2014
|
24 |
S1 |
p. S21-
1 p.
|
artikel
|
| 57 |
OR6-2: IRS-1 promotes embryonic growth of zebrafish through IGF-IR signal-dependent and -independent mechanisms in response to developmental stages and environmental oxygen availability
|
Kamei, H.
|
|
2014
|
24 |
S1 |
p. S16-
1 p.
|
artikel
|
| 58 |
OR2-5: Linkage of reproductive development, fat metabolism and lifespan by the RGD-motif of IGFBP-2 in female transgenic mice
|
Hoeflich, A.
|
|
2014
|
24 |
S1 |
p. S9-
1 p.
|
artikel
|
| 59 |
OR3-3: Liver-specific (LiGHRKO) and fat-specific (FaGHRKO) growth hormone receptor gene disrupted mice demonstrate paradoxical longevity and provide evidence for GH stimulated liver/adipose tissue-crosstalk
|
List, E.O.
|
|
2014
|
24 |
S1 |
p. S10-
1 p.
|
artikel
|
| 60 |
OR3-6: Loss of acyl-ghrelin signalling in male ghrelin-O-acyltransferase knock-out mice results in reduced pulsatile growth hormone secretion and a derangement of GH pulse pattern
|
Xie, T.Y.
|
|
2014
|
24 |
S1 |
p. S11-
1 p.
|
artikel
|
| 61 |
OR5-1: Mechanism of activation of JAK2 by growth hormone
|
Waters, M.J.
|
|
2014
|
24 |
S1 |
p. S14-
1 p.
|
artikel
|
| 62 |
OR8-5: Novel mechanisms by which Nedd4-IRS-2 complexes enhance IGF-I signals, and their roles in IGF-I action in prostate cancer cell proliferation
|
Fukushima, T.
|
|
2014
|
24 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 63 |
OR3-5: NPY neurons as a critical hypothalamic node for the control of GH release relative to food intake
|
Huang, L.
|
|
2014
|
24 |
S1 |
p. S11-
1 p.
|
artikel
|
| 64 |
OR7-7: Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multicenter, randomized study (PAOLA)
|
Fleseriu, M.
|
|
2014
|
24 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 65 |
OR5-2: Rabbits are a suitable animal model for the pre-clinical development of growth hormone agonists and antagonists
|
Bielohuby, M.
|
|
2014
|
24 |
S1 |
p. S14-
1 p.
|
artikel
|
| 66 |
OR4-1: Randomised controlled clinical trial contrasting current GH doses with dose based on IGF-I titration in children born small for gestational age (NESGAS)
|
Jensen, R.B.
|
|
2014
|
24 |
S1 |
p. S12-
1 p.
|
artikel
|
| 67 |
OR8-3: Role of deubiquitinase USP7 in signalling through IGF-1R
|
Worrall, C.
|
|
2014
|
24 |
S1 |
p. S22-
1 p.
|
artikel
|
| 68 |
OR4-3: Safety and effectiveness of Increlex® therapy in children enrolled in the Increlex Growth Forum Database (IGFD) in Europe: 4-year interim results
|
Bang, P.
|
|
2014
|
24 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 69 |
OR7-6: Safety and efficacy of ARX201: six month dose-ranging study of a novel long-acting pegylated growth hormone in young adults with growth hormone deficiency
|
Racz, K.
|
|
2014
|
24 |
S1 |
p. S20-
1 p.
|
artikel
|
| 70 |
OR7-3: Safety and efficacy results of a 6 month, randomized, multicenter trial of a novel long-acting rhGH (VRS-317) in naïve to treatment, pre-pubertal children with GH deficiency
|
Bright, G.M.
|
|
2014
|
24 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 71 |
OR7-5: Safety, tolerability, pharmacokinetics and pharmacodynamics of TV-1106, a new long-acting treatment for growth hormone deficiency
|
CohenBarack, O.
|
|
2014
|
24 |
S1 |
p. S19-
1 p.
|
artikel
|
| 72 |
OR8-8: Serum IGF-I measured longitudinally during pre-school years - relation to gender, body size, and nutrition such as essential fatty acids and vitamin D
|
Dahlgren, J.
|
|
2014
|
24 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 73 |
OR6-5: Sexual dimorphism of insulin like growth factor I in exercise
|
Munive Herrera, V.A.
|
|
2014
|
24 |
S1 |
p. S17-
1 p.
|
artikel
|
| 74 |
OR1-5: Short-term low dose GH therapy improves insulin sensitivity but does not affect cortisol metabolism and ectopic fat accumulation in GH deficient adults
|
Yuen, K.C.J.
|
|
2014
|
24 |
S1 |
p. S6-
1 p.
|
artikel
|
| 75 |
OR3-1: Spatial learning, memory and signaling cross-talk: genomic and behavioral analysis in wild type versus GH modified (bGH & GHA) mice
|
Basu, A.
|
|
2014
|
24 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 76 |
OR1-4: Successful GH treatment for severe growth failure in pediatric patients with anorexia nervosa
|
Fjellestad-Paulsen, A.
|
|
2014
|
24 |
S1 |
p. S6-
1 p.
|
artikel
|
| 77 |
OR6-4: Sustained IGF-II production is necessary for adult neurogenesis
|
Ziegler, A.N.
|
|
2014
|
24 |
S1 |
p. S17-
1 p.
|
artikel
|
| 78 |
OR8-6: The anti-IGF signaling agents increase the efficacy of Trabectedin in Ewing sarcoma
|
Garofalo, C.
|
|
2014
|
24 |
S1 |
p. S23-
1 p.
|
artikel
|
| 79 |
OR2-3: The Cardin-Weintraub Motif present in IGFBP-2 is required for growth and function of the mouse brain
|
Schindler, N.
|
|
2014
|
24 |
S1 |
p. S8-
1 p.
|
artikel
|
| 80 |
OR4-4: The causal role of IGFs and IGFBPs in prostate cancer: a Mendelian randomization study
|
Bonilla, C.
|
|
2014
|
24 |
S1 |
p. S13-
1 p.
|
artikel
|
| 81 |
OR5-4: The choice of growth hormone receptor signalling pathway determines longevity
|
Chhabra, Y.
|
|
2014
|
24 |
S1 |
p. S15-
1 p.
|
artikel
|
| 82 |
OR4-6: The expression of insulin-like growth factor type 1 receptor (IGF1R) is increased in obese children
|
Ricco, R.C.
|
|
2014
|
24 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 83 |
OR2-2: The mitochondrial peptide humanin has fasting mimetic activity leading to suppression of circulating IGF-I and increases in IGFBP-1 levels
|
Xiao, J.
|
|
2014
|
24 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 84 |
OR7-2: The MOD-4023 story; a long acting GH from proof of concepts in animal models to growth hormone deficient populations clinical studies (adults and pediatric )
|
Hart, G.
|
|
2014
|
24 |
S1 |
p. S18-
1 p.
|
artikel
|
| 85 |
OR1-3: The molecular mechanism of dominantly inherited short stature caused by GH polymers
|
Wu, Z.
|
|
2014
|
24 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 86 |
Plenary Lectures
|
|
|
2014
|
24 |
S1 |
p. viii-
1 p.
|
artikel
|
| 87 |
PO3-14: Activated STAT3 as a possible resistance mechanism to the anti-tumour effects of an anti-IGF-II neutralising antibody in hepatocellular carcinoma
|
Greenall, S.A.
|
|
2014
|
24 |
S1 |
p. S34-
1 p.
|
artikel
|
| 88 |
PO3-13: ADLib® system: a versatile antibody discovery platform
|
Hashimoto, S.
|
|
2014
|
24 |
S1 |
p. S34-
1 p.
|
artikel
|
| 89 |
PO4-1: Alpha-fetoprotein at birth: an early marker of circulating IGF-I in preterm infants
|
Kistner, A.
|
|
2014
|
24 |
S1 |
p. S49-
1 p.
|
artikel
|
| 90 |
PO3-16: Altered mouse adipose tissue IGF-1 expression influences glucose control
|
Trost, J.
|
|
2014
|
24 |
S1 |
p. S35-
1 p.
|
artikel
|
| 91 |
PO1-1: Analysis of chimeric mice using growth hormone receptor gene disrupted (GHRKO) derived bone-marrow to investigate the role of GH signaling in the infiltration of proinflammatory macrophages in adipose tissue
|
Herpy, J.
|
|
2014
|
24 |
S1 |
p. S26-
1 p.
|
artikel
|
| 92 |
PO2-2: An evaluation of the safety and usability of FlexPro® 30 mg/3 mL, for the delivery of Norditropin® in patients requiring growth hormone (GH) therapy
|
Kappelgaard, A.-M.
|
|
2014
|
24 |
S1 |
p. S39-
1 p.
|
artikel
|
| 93 |
PO2-7: Assessing the impact of storage flexibility on daily life for patients and caregivers taking/administering growth hormone (GH)
|
Kappelgaard, A.-M.
|
|
2014
|
24 |
S1 |
p. S41-
1 p.
|
artikel
|
| 94 |
PO2-25: Assessment of hydration based on bioelectrical impedance analysis (BIA) and arm muscle area (AMA) in treatment-naïve adult patients with growth hormone deficiency (GHD)
|
Jørgensen, J.O.L.
|
|
2014
|
24 |
S1 |
p. S47-
1 p.
|
artikel
|
| 95 |
PO2-6: Autocrine human growth hormone (hGH) promotes metabolic reprogramming in breast cancer cells to adapt to available glucose
|
Banerjee, A.
|
|
2014
|
24 |
S1 |
p. S41-
1 p.
|
artikel
|
| 96 |
PO3-12: Balancing the IGF-1R-Mdm2-p53 axis as novel therapeutic strategy in skin melanoma
|
Girnita, A.
|
|
2014
|
24 |
S1 |
p. S33-
1 p.
|
artikel
|
| 97 |
PO4-4: Cerebrospinal fluid and serum levels of growth hormone (GH), insulin-like-growth factor-I (IGF-1), insulin-like growth factor binding protein -3 (IGFBP-3) and ghrelin in patients with bacterial and tuberculous meningitis
|
Akinci, A.
|
|
2014
|
24 |
S1 |
p. S50-
1 p.
|
artikel
|
| 98 |
PO5-1: Clinical relevance of serum prolactin level in perimenopausal women with metabolic syndrome
|
Pchelin, I.
|
|
2014
|
24 |
S1 |
p. S52-
1 p.
|
artikel
|
| 99 |
PO4-9: Complex tissue-specific epigenotypes in Russell Silver syndrome with 11p15 ICR1 hypomethylation: major consequences for the diagnosis
|
Azzi, S.
|
|
2014
|
24 |
S1 |
p. S51-S52
2 p.
|
artikel
|
| 100 |
PO3-10: Constitutive IRS1 expression causes cell competition, leading to defect in myogenic differentiation
|
Hakuno, F.
|
|
2014
|
24 |
S1 |
p. S33-
1 p.
|
artikel
|
| 101 |
PO3-5: Developing predictive determinants of IGF/INS targeted therapies in ovarian cancer patient tumors and primary tumorgrafts
|
Becker, M.
|
|
2014
|
24 |
S1 |
p. S31-
1 p.
|
artikel
|
| 102 |
PO2-12: Development and characterization of manufacturing process of MOD-4023, a long acting human growth hormon to support clinical and commercial supply
|
Hershkovitz, O.
|
|
2014
|
24 |
S1 |
p. S42-S43
2 p.
|
artikel
|
| 103 |
PO3-9: Effects of endurance training on somatic growth in a rat model of chronic kidney disease (CKD)
|
Troib, A.
|
|
2014
|
24 |
S1 |
p. S32-
1 p.
|
artikel
|
| 104 |
PO2-24: Elevated spontaneous trough GH levels are associated with Lipoprotein (a) in short prepubertal children with high waist-hip ratio
|
Decker, R.
|
|
2014
|
24 |
S1 |
p. S46-
1 p.
|
artikel
|
| 105 |
PO2-11: Evidence for truncated somatostatin receptor 5 modulation of therapy response to somatostatin analogues in two patients with acromegaly and severe headache
|
Marina, D.
|
|
2014
|
24 |
S1 |
p. S42-
1 p.
|
artikel
|
| 106 |
PO4-7: Functional selectivity of the insulin-like growth factor type 1 receptor (IGF-1R) signaling: therapeutic implications for cancer treatment
|
Girnita, L.
|
|
2014
|
24 |
S1 |
p. S51-
1 p.
|
artikel
|
| 107 |
PO2-14: Genetic markers of insulin resistance are associated with growth hormone response in short SGA children - the North European SGA study (NESGAS)
|
Jensen, R.B.
|
|
2014
|
24 |
S1 |
p. S43-
1 p.
|
artikel
|
| 108 |
PO2-23: Growth and puberty of children with congenital isolated growth hormone deficiency
|
Smuel, K.
|
|
2014
|
24 |
S1 |
p. S46-
1 p.
|
artikel
|
| 109 |
PO3-7: Growth hormone addition to medium in HepG2 cell culture: influence on IGF-I and IGF-II production
|
Knaack, H.
|
|
2014
|
24 |
S1 |
p. S32-
1 p.
|
artikel
|
| 110 |
PO2-21: Growth hormone deficiency amongst nasopharyngeal cancer survivors
|
Ratnasingam, J.
|
|
2014
|
24 |
S1 |
p. S45-
1 p.
|
artikel
|
| 111 |
PO2-19: Growth hormone therapy in a child with Kearns Sayre syndrome and chronic kidney disease
|
Sng, A.
|
|
2014
|
24 |
S1 |
p. S44-S45
2 p.
|
artikel
|
| 112 |
PO2-10: Growth hormone treatment: case studies in Dr Soetomo Hospital
|
Rochmah, N.
|
|
2014
|
24 |
S1 |
p. S42-
1 p.
|
artikel
|
| 113 |
PO2-9: Growth without growth hormone
|
Rochmah, N.
|
|
2014
|
24 |
S1 |
p. S41-S42
2 p.
|
artikel
|
| 114 |
PO2-13: Human growth hormone and human prolactin possess autocrine roles in hepatocellular carcinoma
|
Zhang, M.
|
|
2014
|
24 |
S1 |
p. S43-
1 p.
|
artikel
|
| 115 |
PO3-17: Hypermethylation and hypomethylation of IGF-II DMRO (Insulin like growth factors-II Differentially Methylated Region) correlated to increased or decreased expression of IGF-II in breast cancer cells and paired breast tissues of African American and Caucasian breast cancer patients
|
Radhakrishnan, V.K.
|
|
2014
|
24 |
S1 |
p. S35-
1 p.
|
artikel
|
| 116 |
PO2-16: IGF-1 as nutritional marker
|
Kim, J.H.
|
|
2014
|
24 |
S1 |
p. S44-
1 p.
|
artikel
|
| 117 |
PO3-19: IGF-1 receptor C terminal tail phosphorylation on Y1250 in cancer cells
|
O Shea, S.P.
|
|
2014
|
24 |
S1 |
p. S35-S36
2 p.
|
artikel
|
| 118 |
PO3-4: IGF-1-regulated PDLIM2 protein is required for epithelial to mesenchymal transition (EMT) and transcription factor stability
|
Cox, O.T.
|
|
2014
|
24 |
S1 |
p. S31-
1 p.
|
artikel
|
| 119 |
PO4-5: Insulin like growth factor-1 therapy in five patients with growth hormone insensitivity
|
Ersoy, B.
|
|
2014
|
24 |
S1 |
p. S50-
1 p.
|
artikel
|
| 120 |
PO2-15: Insulin tolerance test and GHRH plus arginine in the reassessment of pituitary function at adult height achievement
|
Di Iorgi, N.
|
|
2014
|
24 |
S1 |
p. S44-
1 p.
|
artikel
|
| 121 |
PO3-18: Lipopolysaccharide (LPS) treatment increased the protein levels of GKAP42 (42-kDa cGMP-dependent protein kinase anchoring protein) followed by inhibition of insulinmediated glucose transporter (GLUT) 4 translocation to the plasma membrane and glucose uptake in adipocytes
|
Yu, B.-C.
|
|
2014
|
24 |
S1 |
p. S35-
1 p.
|
artikel
|
| 122 |
PO3-2: Modulation of IGFBP1 protein expression by metformin
|
Ansurudeen, I.
|
|
2014
|
24 |
S1 |
p. S30-
1 p.
|
artikel
|
| 123 |
PO3-1: Molecular, biochemical, histological, and phylogenetic characterizations of insulin-like peptides and insulin/insulinlike growth factor (IGF)-I receptors in rotifers
|
Ozaki, Y.
|
|
2014
|
24 |
S1 |
p. S30-
1 p.
|
artikel
|
| 124 |
PO2-3: Multiple doses of a reversible albumin-binding growth hormone derivative demonstrate no differences in PK and PD between Japanese and non-Asian subjects
|
Højby Rasmussen, M.
|
|
2014
|
24 |
S1 |
p. S40-
1 p.
|
artikel
|
| 125 |
PO2-26: Pharmacokinetic (PK) and pharmacodynamic (PD) modeling of MOD-4023 (a long-acting hGH-CTP) in adults and growth hormone (GH)-deficient children
|
Fisher, D.
|
|
2014
|
24 |
S1 |
p. S47-
1 p.
|
artikel
|
| 126 |
PO3-11: Porphyra yezoensis peptide stimulates the proliferation of IEC-6 cells by activating the insulin-like growth factor-I receptor signaling pathway
|
Nam, T.-J.
|
|
2014
|
24 |
S1 |
p. S33-
1 p.
|
artikel
|
| 127 |
PO2-4: Pregnancy in acromegaly patients treated with pegvisomant
|
Van der Lely, A.J.
|
|
2014
|
24 |
S1 |
p. S40-
1 p.
|
artikel
|
| 128 |
PO3-15: Regulation of IGF-1 at the transcription level by IGFBP-1
|
Ansurudeen, I.
|
|
2014
|
24 |
S1 |
p. S34-
1 p.
|
artikel
|
| 129 |
PO2-20: Safety evaluation of long-term recombinant growth hormone (rGH) treatment in paediatric patients: interim analysis of NordiNet® International Outcome Study (IOS)
|
Sävendahl, L.
|
|
2014
|
24 |
S1 |
p. S45-
1 p.
|
artikel
|
| 130 |
PO3-6: Serum concentrations of IGF-I and IGF-II proceed in a reciprocal manner during a physiological cycle and maternal IGFBP-4 concentration was lower in pregnant than in not pregnant dairy heifers during early pregnancy
|
Meyerholz, M.
|
|
2014
|
24 |
S1 |
p. S31-
1 p.
|
artikel
|
| 131 |
PO4-6: Serum levels of IGF-I and IGFBP-1 in Indian diabetic population
|
Tekle, M.
|
|
2014
|
24 |
S1 |
p. S50-S51
2 p.
|
artikel
|
| 132 |
PO4-3: Serum levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3) in women with cervical cancer
|
Cho, D.H.
|
|
2014
|
24 |
S1 |
p. S50-
1 p.
|
artikel
|
| 133 |
PO5-2: Serum prolactin level in chronic kidney disease
|
Vasilkova, O.
|
|
2014
|
24 |
S1 |
p. S52-
1 p.
|
artikel
|
| 134 |
PO2-5: Severe headache relieved by short-acting somatostatin analogue in a patient with Acromegaly resistant to longacting somatostatin analogues
|
Hoybye, C.
|
|
2014
|
24 |
S1 |
p. S40-
1 p.
|
artikel
|
| 135 |
PO1-5: Socs 2 plays no major role in the increased expression of fibrotic genes in the remnant kidney
|
Assadi, M.H.
|
|
2014
|
24 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 136 |
PO2-17: Soluble alpha-Klotho and vitamin D in acromegaly
|
Bolanowski, M.
|
|
2014
|
24 |
S1 |
p. S44-
1 p.
|
artikel
|
| 137 |
PO2-8: Specific measurement of human growth hormone oligomers in blood and its possible clinical application
|
Wu, Z.
|
|
2014
|
24 |
S1 |
p. S41-
1 p.
|
artikel
|
| 138 |
PO4-8: Subclinical hypothyroidism is associated with low IGF-I levels and decreased growth velocity
|
Bellini, H.
|
|
2014
|
24 |
S1 |
p. S51-
1 p.
|
artikel
|
| 139 |
PO3-3: The hepatic expression of GHR and SOCS2 mRNA is increased before ovulation during the follicular phase in dairy cattle
|
Mense, K.
|
|
2014
|
24 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 140 |
PO2-1: The pathogenesis of anti-PIT-1 antibody syndrome - the involvement of PIT-1-reactive cytotoxic T lymphocytes
|
Bando, H.
|
|
2014
|
24 |
S1 |
p. S39-
1 p.
|
artikel
|
| 141 |
PO3-8: Understanding and targeting the IGFBP-3/IGFBP-3R system in obesity related disorders: IGFBP-3R agonists as preventive and therapeutic interventions for obesity-induced IR and T2DM
|
Cai, Q.
|
|
2014
|
24 |
S1 |
p. S32-
1 p.
|
artikel
|
| 142 |
PO2-22: Usability and safety of FlexPro® PenMate®, a growth hormone (GH) injection system, in patients, caregivers and healthcare professionals
|
Wen, Y.
|
|
2014
|
24 |
S1 |
p. S46-
1 p.
|
artikel
|
| 143 |
PO4-2: Variations in growth in relation to IGF-I levels in children born very preterm and target height influences from birth to 3-years of age
|
Kistner, A.
|
|
2014
|
24 |
S1 |
p. S49-S50
2 p.
|
artikel
|
| 144 |
Program at a Glance
|
|
|
2014
|
24 |
S1 |
p. vii-
1 p.
|
artikel
|
| 145 |
SY1-7: Abuse of growth hormone
|
Strasburger, C.J.
|
|
2014
|
24 |
S1 |
p. S2-
1 p.
|
artikel
|
| 146 |
SY1-3: Dosing and Monitoring GH treatment in children born SGA
|
Léger, J.
|
|
2014
|
24 |
S1 |
p. S1-
1 p.
|
artikel
|
| 147 |
SY1-2: Dosing and Monitoring GH Treatment in GH Deficient Children
|
Cohen, P.
|
|
2014
|
24 |
S1 |
p. S1-
1 p.
|
artikel
|
| 148 |
SY1-4: Dosing and monitoring GH treatment in Turner syndrome
|
Tanaka, T.
|
|
2014
|
24 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 149 |
SY1-6: Growth hormone and sarcopenia - future aspects
|
Thorner, M.
|
|
2014
|
24 |
S1 |
p. S2-
1 p.
|
artikel
|
| 150 |
SY1-5: Growth hormone replacement in adult growth hormone deficiency: long-term efficacy and safety
|
Johannsson, G.
|
|
2014
|
24 |
S1 |
p. S2-
1 p.
|
artikel
|
| 151 |
SY2-4: IGFBP-2 in Cancer: From The Matrix to The Inside Job
|
Russo, V.C.
|
|
2014
|
24 |
S1 |
p. S3-
1 p.
|
artikel
|
| 152 |
SY2-1: Insulin-like growth factor 2 mRNA binding proteins (IMP/IGF2BP) as mRNA safe houses in cancer and development
|
Christiansen, J.
|
|
2014
|
24 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 153 |
SY2-5: The G protein estrogen receptor (GPER) is involved in IGF-I/insulin signaling in cancer cells
|
Maggiolini, M.
|
|
2014
|
24 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 154 |
SY2-2: The IRS proteins: determinants of IGF-1R signaling and tumor metabolism
|
Shaw, L.
|
|
2014
|
24 |
S1 |
p. S3-
1 p.
|
artikel
|
Tijdschrift beschrijving